Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 12.9.2013 | EN | Official Journal of the European Union | C 263/11 |

---

Prior notification of a concentration

(Case COMP/M.6979 — DSM R&D Solutions/Maastricht UMC-Holding/Device Company JV)

Candidate case for simplified procedure

(Text with EEA relevance)

2013/C 263/12

|  |  |
| --- | --- |
| 1. | On 5 September 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004[(1)](#ntr1-C_2013263EN.01001101-E0001) by which the undertakings DSM R&D Solutions BV (‘DSM R&D Solutions’, the Netherlands), belonging to the group Koninklijke DSM NV (‘DSM’, the Netherlands), and Maastricht UMC-Holding BV (‘Maastricht UMC-Holding’, the Netherlands) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Device Company BV (‘Device Company JV’, the Netherlands) by way of purchase of shares in a newly-created company constituting a joint venture. |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 2. | The business activities of the undertakings concerned are:   |  |  | | --- | --- | | — | for DSM: human and animal nutrition, pharmaceuticals, performance materials and industrial chemicals, |  |  |  | | --- | --- | | — | for Maastricht UMC-Holding: creation and holding of legal entities aimed at commercialising scientific discoveries made in the health, nutrition and materials fields, |  |  |  | | --- | --- | | — | for Device Company JV: the production and sale of mobile infrared devices capable of measuring the constituent elements of pharmaceuticals, drugs and potentially other products, as an alternative to laboratory research. | |

|  |  |
| --- | --- |
| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation[(2)](#ntr2-C_2013263EN.01001101-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6979 — DSM R&D Solutions/Maastricht UMC-Holding/Device Company JV, to the following address:   |  | | --- | | European Commission | | Directorate-General for Competition | | Merger Registry | | 1049 Bruxelles/Brussel | | BELGIQUE/BELGIË | |

---

[Top](#document1)